Market Overview

Boehringer Ingelheim launches the initiative In Reach Africa to address key healthcare infrastructure and access priorities across Africa

  • ‘In Reach Africa' to facilitate quality and innovative human and
    animal healthcare access across the continent
  • Series of activities and workshops already started
  • Initiative underlines the company's desire to provide more health
    and improve lives of patients on the continent

Boehringer Ingelheim, one of the world's leading pharmaceutical
companies, announced recently the launch of the ‘In Reach Africa'
program, an initiative aimed at facilitating quality and innovative
human and animal healthcare access across the African continent.

The program is set to kick off in Kenya and to expand throughout major
African markets including Nigeria, Ghana, Ethiopia, Uganda, Mozambique,
Tanzania, Zambia, Zimbabwe and Rwanda. It comprises a range of key
elements that aim at adding more value to overall health systems, in an
effort to drive access to care, support with the development of
innovative health solutions, creating community based partnerships and
raising awareness around key disease areas as well as prevention

A series of activities and workshops that are the building blocks of the
newly launched program already started in July as for example the
‘Making More Health (MMH) Accelerator program. This program supports
social health entrepreneurs to strengthen and scale their work, by
bringing some of the best experiences in social and health innovation as
well as global health to improve access across Sub-Saharan Africa.
Empowering individuals is a core part of the initiative's strategy and
the fundamental element throughout ‘In Reach Africa'.

MMH is a long-term global initiative driven by Boehringer Ingelheim in
partnership with Ashoka, a global non-governmental organization. Through
MMH in Kenya, Boehringer Ingelheim and Askoka supported iSikCure, an
application developed to improve access to quality care and safe
medicine. In 2017, Boehringer Ingelheim, in partnership with Access Afya
and PharmAccess, launched Akiba Ya Roho, a micro-savings program geared
towards driving more healthcare awareness and overall understanding and
management of non-communicable disease in some rural areas within Kenya.

"‘In Reach Africa' shares a vision of driving accessibility,
sustainability and innovation through enhancing health systems in Africa
by providing an accessible range of medication and healthcare solutions,
increasing awareness of key disease priorities through reach and
enriching knowledge and education initiatives. In doing so, it is
designed to add more value to the socioeconomic structure by working
with and supporting low income families on multiple fronts," said Yew
Looi Liew, Head of Corporate Division Prescription Medicine Emerging
Markets at Boehringer Ingelheim.

Reducing the avoidable burden caused by Non Communicable Diseases (NCDs)
is central to the initiative. (NCDs) are a silent epidemic in low and
middle-income countries, which account for 75 per cent of global NCDs
deaths. Africa is expected to experience 3.9 million NCD-related deaths
a year by 2020, a rise of more than 20 per cent.1
"Accordingly, we need to commit ourselves as an organization to working
together with all other healthcare players to build an infrastructure
that is sustainable, and one, which can ensure needed therapies are
available in even the most remote areas. At Boehringer Ingelheim, we
believe that everyone should have access to good health, no matter where
they live," commented Enrique Manzoni, Regional Managing Director –
Middle East, Turkey, Africa (META) at Boehringer Ingelheim.

Please click on the following link for ‘Notes to Editors' and

View Comments and Join the Discussion!